Skip to main content
ZVRA logo

ZVRA · Zevra Therapeutics, Inc.

Track ZVRA — free
$9.19 -0.09 (-0.97%)
Market Cap
$552.20M
Shares
59.50M
Volume · Nov 19 68.92K Avg daily vol (3M) 954.6K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$9.28 Open$9.31 Day$9.15–9.49 52W close$8.10–14.75 Avg vol 30d967K Short int6.6M · 11.0% of shares · 9.5d Short vol54% Last earningsNov 3, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Mar 8, 2027 Est · unconfirmed · in 16 wks

Latest documents

2026
Nov 3
Earnings call
Revenue rose 45% to $37.8 million

Zevra reported third-quarter total net revenue of $37.8 million, up 45%, net income of $19.2 million and $270.9 million in cash, cash equivalents, and investments. MyPyFA generated $34 million in U.S. net sales; an SNDA is planned for the first quarter of 2027.

6 source passages
Zevra's focus on accelerating time to NPC diagnosis In the third quarter of 2026, We generated total net revenue of $37.8 million, which was an increase of $11.7 million, or 45%, compared to $26.1 million in Q3 2025. Net income for the third quarter of 2026 was $19.2 million, or $0.31 per basic and $0.26 per diluted share, compared to a net loss of $0.5 million, or $0.01 per basic and diluted share, for the same quarter a year ago. As of September 30th, 2026, total cash, cash equivalents, and investments were $270.9 million, which was an increase of approximately $10.7 million compared to June 30th, 2026. net U.S. product revenue from MyPyFA was $34 million. we expect to file an SNDA in the first quarter of 2027. Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue reaches $113.6 million; net income totals $65.9 million

Zevra Therapeutics reported nine-month 2026 revenue of $113.6 million and net income of $65.9 million, including a $43.3 million gain from selling assets under the Commave Settlement Agreement. Cash, cash equivalents and investments totaled $270.9 million.

Revenue $37.76M ▲ 44.9% Net income $19.21M Diluted EPS $0.26
Read from the MD&A section
3 source passages
In February 2023, we changed our name to Zevra Therapeutics, Inc. Net income for the nine months ended September 30, 2026, was $65.9 million, and was comprised of revenue of $113.6 million, a gain on sale of future royalties, intellectual property, and other assets, net, of $43.3 million under the Commave Settlement Agreement As of September 30, 2026, we had cash, cash equivalents and investments of $270.9 million. Open the document at this passage
Nov 3
Current report 8-K
Q3 revenue rises 45% as MIPLYFFA sales reach $34.0 million

Zevra Therapeutics reported $37.8 million in Q3 2026 net revenue, up 45% from Q3 2025, including $34.0 million from MIPLYFFA. Net income was $19.2 million, and cash, cash equivalents and investments totaled $270.9 million as of September 30, 2026.

Financial results
5 source passages
BOSTON, Mass., November 3, 2026 -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today reported its financial results for the third quarter ended September 30, 2026. 45% increase in total net revenue over Q3 2025 Revenue, Net: $37.8 million for Q3 2026, which includes $34.0 million of MIPLYFFA net revenue, $0.2 million of OLPRUVA net revenue, and $3.6 million in net reimbursements from our global EAP. This was an increase in total net revenue of $11.7 million compared to $26.1 million in Q3 2025. Net income (loss): Net income of $19.2 million, or $0.31 per basic and $0.26 diluted share for Q3 2026, compared to a net (loss) of $(0.5) million, or $(0.01) per basic and diluted share for Q3 2025. Cash Position: Cash, cash equivalents and investments were $270.9 million as of September 30, 2026. Based on its current operating forecast, the Company believes available financial resources are sufficient to execute on its strategic priorities. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$147.76M
Trailing 12 months
Net income (TTM)
$78.02M
Trailing 12 months
Revenue growth YoY
+44.9%
Year over year
Operating margin
60.8%
Trailing 12 months
P / E (TTM)
7.7
Trailing earnings · reciprocal yield 13.0%
FCF yield
—
TTM · current market cap
Return on invested capital
66.7%
Trailing 12 months
Net cash
$122.15M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+10.3%
Year over year · more shares
Price change (1Y)
-4.3%
Trailing year
Short interest
11.0%
Latest settlement · 9.5 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 3, 2026
Q3 FY26

TL;DR. Q3 net revenue rose 45% to $37.8 million, including $34.0 million of MIPLYFFA revenue, and Zevra reported $19.2 million of net income, $270.9 million of cash, cash equivalents and investments, 197 cumulative enrollment forms, 69% payer coverage, and continued Phase 3 DiSCOVER enrollment. Operating and product costs increased, European approval remains unresolved, the pediatric expansion represents a relatively small patient population and is not expected to increase TAM prevalence, and MIPLYFFA carries stated serious safety and withdrawal risks.

Bullish
  • + Q3 total net revenue increased 45% to $37.8 million, including $34.0 million of MIPLYFFA net revenue. new
  • + Zevra reported Q3 net income of $19.2 million, or $0.31 per basic and $0.26 per diluted share, versus a $0.5 million net loss a year earlier. new
  • + Cash, cash equivalents and investments increased approximately $10.7 million from June 30, 2026 to $270.9 million at September 30, 2026. new
  • + Management plans to file a pediatric MIPLYFFA sNDA in Q1 2027, while cited patent protection extends to 2041 and U.S. orphan drug exclusivity runs through 2031. new
  • + The Phase 3 DiSCOVER trial enrolled six additional celiprolol patients in Q3 to reach 72, and management is pursuing a potential accelerated submission strategy with the FDA. new
Bearish
  • − European approval remains unresolved while arimoclomol's Marketing Authorization Application is undergoing reexamination. new
  • − Management characterized the under-24-month label expansion as a relatively small patient population, estimated in the ballpark of 5%. new
  • − MIPLYFFA's prescribing information identifies serious adverse reactions and withdrawal risks. new
  • − The pediatric expansion is not expected to increase total addressable market prevalence. new
  • − Cost of product revenue increased to $1.8 million in Q3 2026 from $1.2 million in Q3 2025, excluding intangible asset amortization. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross Death cross
Price vs 200-day avg −14%
below
Price vs 50-day avg −14%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 18%
mid-range
Momentum
relative strength
Weak
1-month return −10%
trailing
6-month return −20%
trailing
YTD return +4%
this year
Relative strength −16%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) Death cross
50d $11 › 200d $11 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +41 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.02% of shares out · ▲ +5.3% MoM · 9.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
177 holders — near 3-yr high, broad support
Squeeze score 70
elevated · 0–100
Fundamentals
Excellent
Revenue growth +351%
Y/Y
EPS growth +159%
Y/Y
Free cash flow $-2.4M
Valuation P/E 7.2
below peers
Buyback $50.0M
authorized
Balance sheet $478.0K
net cash
Quant / Vol
risk profile
Very High
Volatility 63%
annualized · 1-yr
Max drawdown −38%
past year
ATR 6.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 8, 2024
Revenue · three months ended June 30, 2024 $4.2M – $4.6M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
Death cross Bearish
Price vs 200-day avg
−14% Bearish
Price vs 50-day avg
−14% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
18% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) Death cross
50d $11 › 200d $11 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +41 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.02% of shares out · ▲ +5.3% MoM · 9.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
177 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $8 Now $9 · 18% Range high $15
vs 200-day avg -14% vs 50-day avg -14% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted net income per diluted share non-GAAP $0.25 Q2 2026 —
Adjusted quarterly net income non-GAAP $15.2M Q2 2026 —
Confirmed events in the Phase 3 DiSCOVER trial 3 Q2 2026 —
Fully diluted common shares 69,298,105 As of June 30, 2026 —
Market access (covered lives) 69% Q2 2026 —
MIPLYFFA prescription enrollment forms 14 Q2 2026 —
Patients enrolled in the global Expanded Access Program 132 As of June 30, 2026 —
Patients enrolled in the Phase 3 DiSCOVER trial of celiprolol 66 Q2 2026 —
revenue related to the global EAP $9M three months ended June 30, 2026 filing —
revenue under the AZSTARYS License Agreement $0.3M three months ended June 30, 2026 filing —
sales of OLPRUVA $0.2M three months ended June 30, 2026 filing —
Total MIPLYFFA prescription enrollment forms since product launch 184 Q2 2026 —
Total shares of common stock outstanding 59,341,906 As of June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ZVRA
Zevra Therapeutics, Inc.
this stock
$552.20M +3.6% +350.9% 7.2 11.0%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
177
% held
80.0%
Net QoQ
+2.8M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
172
View
Short & Settlement
Short Interest Rising
Shares short
6.6M
Days to cover
9.5d
Change
+330.8K sh
View
Short Volume
Short vol %
54%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
153
Value
$1.6K
As of
Oct 22, 2026
View
Off-Exchange
Off-exchange %
38.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$83.2M
EPS diluted
$1.35
View
Buybacks
Authorized
$50.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 3, 2026
This year
15

Zevra Therapeutics reported $37.8 million in Q3 2026 net revenue, up 45% from Q3 2025, including $34.0 million from MIPLYFFA. Net income was $19.2 million, and cash, cash equivalents and investments totaled $270.9 million as of September 30, 2026.

View
Proposed Sales
Value
$227.8K
Shares
20.0K
Filed
Oct 13, 2026
View
Exempt Offerings
Offering
$39.1M
Filed
Jun 22, 2021
View
Earnings & Events
Webcasts
Last webcast
Nov 3, 2026
View
Investor Relations
Latest news
Zevra Reports Third Quarter 2026…
Published
Nov 3, 2026
View

Performance

5D 20D 120D MTD YTD
ZVRA -21.7% -10.4% -19.9% -9.7% +3.6%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -17.8% -4.9% -16.5% -6.4% -3.5%

Capital returns

Buyback program · as of Dec 20, 2021
Authorized
$50.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1434647 CUSIP 488445206 13F (30d) 188 filings 164 filers Visit website Investor relations